UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
114,46 $
arrow_downward
-0,87%(-1,01) 1D
16 қаз., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJY...
Open
114,95 $
High
115,28 $
Low
114,23 $
Mkt. cap
39,39 млрд
Avg. vol.
53,31 мың
Volume
70,57 мың
52-wk high
168,76 $
52-wk low
110,55 $
Beta
0,57
Shares outstanding
389,01 млн
No. of employees
9 мың
Open
114,95 $
High
115,28 $
Low
114,23 $
Mkt. cap
39,39 млрд
Avg. vol.
53,31 мың
Volume
70,57 мың
52-wk high
168,76 $
52-wk low
110,55 $
Beta
0,57
Shares outstanding
389,01 млн
No. of employees
9 мың
News stories
From web sources and news partners
TradingView
·
1 сағат бұрын
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight
The Fintech Times
·
23 минут бұрын
First Digital to List on Nasdaq via SPAC Deal at $250m Valuation
Yahoo Finance
·
1 сағат бұрын
Anthropic IPO Buzz Has Investors Watching Nasdaq Stock And ECM Fee Winners
Bloomberg.com
·
4 сағат бұрын
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB Unsponsored Belgium ADR
CEOJean-Christophe Tellier
Employees9 мың
Founded1928 ж. 18 қаң.
Headquarters-
SectorPharmaceutical industry
Websiteucb.com